| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.1 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |